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Purpose: Vancomycin prescribing requires individualized dosing and monitoring to ensure effi-
cacy, limit toxicity, and minimize resistance. Although there are nationally endorsed guidelines 
from several countries addressing the complexities of vancomycin dosing and monitoring, there 
is limited consideration of how to implement these recommendations effectively.
Methods: We conducted a systematic search of multiple databases to identify relevant compara-
tive studies describing the impact of interventions of educational meetings, implementation of 
guidelines, and dissemination of educational material on vancomycin dosing, monitoring, and 
nephrotoxicity. Effect size was assessed using ORs and pooled data analyzed using forest plots 
to provide overall effect measures.
Results: Six studies were included. All studies included educational meetings. Two studies used 
implementation of guidance, educational meetings, and dissemination of educational materi-
als, one used guidance and educational meetings, one educational meetings and dissemination 
of educational materials, and two used educational meetings solely. Effect sizes for individual 
studies were more likely to be significant for multifaceted interventions. In meta-analysis, the 
overall effect of interventions on outcome measures of vancomycin dosing was OR 2.50 (95% 
CI 1.29–4.84); P< 0.01. A higher proportion of sampling at steady-state concentration was seen 
following intervention (OR 1.95, 95% CI 1.26–3.02; P<0.01). Interventions had no effect on 
appropriate timing of trough sample (OR 2.02, 95% CI 0.72–5.72; P=0.18), attaining target 
concentration in patients (OR 1.50, 95% CI 0.49–4.63; P=0.48, or nephrotoxicity (OR 0.75, 
95% CI 0.42–1.34; P=0.33).
Conclusion: Multifaceted interventions are effective overall in improving the complex task of 
dosing vancomycin, as well as some vancomycin-monitoring outcome measures. However, the 
resulting impact of these interventions on efficacy and toxicity requires further investigation. 
These findings may be helpful to those charged with designing implementation strategies for 
vancomycin guidelines or complex prescribing processes in hospitals.
Keywords: drug monitoring, education, guideline, implementation, intervention, prescribing, 
systematic review, vancomycin
Introduction
Vancomycin is an essential antibiotic that has been in use for six decades.1 Despite 
sustained use, vancomycin remains an inherently challenging drug to prescribe, due to 
the need for individualized dosing and requirement for serum-concentration monitor-
ing to ensure efficacy, minimize nephrotoxicity and limit the development of resistant 
organisms.2–5 Recommendations on how to dose and monitor vancomycin have evolved 
over time.6 These issues, in addition to the greater public health concern of antimicrobial 
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resistance,7 have resulted in a number of professional societ-
ies in the US, Japan, and more recently China publishing their 
own vancomycin guidelines. 8–10 Significant time and expert 
engagement goes into the development of these high-caliber 
guidelines,11 which are sanctioned and advocated by their 
respective countries.12,13 These guidelines provide important 
updated information for clinicians and seek to improve care 
for patients; however, there is a dearth of information as to 
how these guidelines should be implemented into practice 
to fulfill these objectives. The published protocol for the 
development of clinical practice guidelines for therapeutic 
drug monitoring (TDM) of vancomycin by the Chinese Phar-
macological Society is the only one that provides any advice 
on implementation.14 In addition to limited information on 
implementation strategies of these guidelines, there is scant 
evidence on which interventions may be best employed and 
in what combination.
There are a number of published works stating that 
clinicians in numerous fields of medicine often do not 
follow guidelines, including prescribing antibiotics for 
hospitalized patients.15–18 In an effort to address these 
problems, strategies have been advocated by peak national 
bodies concerned with guideline implementation and 
care improvement, such as the UK National Institute for 
Health and Care Excellence, the US Institute of Medicine, 
the Australian National Health and Medical Research 
Council, and more broadly the Guideline International 
Network.12,19–21 Examples of strategies recommended by 
these bodies include implementation of guidelines, edu-
cational meetings, and dissemination of educational mate-
rial.22–24 Determining optimal strategies, employed alone 
or in combination, is critical to inform practice initiatives 
seeking to translate guidelines and their recommendations 
into practice. This systematic review aims to evaluate the 
effect of interventions using education, guideline imple-
mentation, and dissemination of educational resources on 




The protocol for this systematic review was registered 
(CRD42016049147) with PROSPERO, (International Pro-
spective Register of Systematic Reviews, Center for Reviews 
and Dissemination, University of York, UK) in October 2016. 
A protocol for this review has been published.25 The review 
has been reported in accordance with the PRISMA (preferred 
reporting items for systematic reviews and meta-analyses) 
2015 statement.26,27 A PRISMA flow diagram of included 
studies is presented in Figure 1.
Research question
Do interventions (alone or in combination) involving educa-
tion, implementation of guidelines/protocols, or dissemina-
tion of educational materials (printed or electronic) improve 
the prescribing, monitoring, and safety of vancomycin?
Eligibility criteria
Studies included were restricted to the English language. Due 
to a pilot search suggesting a limited number of randomized 
controlled trials, no restrictions were placed on study type, 
which included observational and cohort studies. There were 
no restrictions on year of publication, with databases searched 
back to their inception. The studies included required interven-
tions to influence vancomycin prescribing and monitoring, 
using educational meetings (face to face, online, or continuing 
education), guideline or protocol implementation, dissemina-
tion of educational materials, or multifaceted interventions 
comprising one or more of these. These interventions were 
selected as they are commonly recommended implementation 
strategies that are not cost-prohibitive.20,28 Excluded studies 
were those that used pharmacokinetic modeling based on 
guidelines/protocols/nomograms, compared one guideline 
directly with another (rather than an intervention to imple-
ment the guideline), lacked comparator or baseline data, 
and where postimplementation outcomes excluded patients 
not managed in accordance with the new guideline (so as 
not to bias or misrepresent uptake of the guideline). Studies 
employing interventions where outcomes were exclusively 
based on indication and/or duration of vancomycin therapy 
were also excluded.
Data sources
The database searches were performed in October 2016 
using the predefined search strategy and method described 
in the published protocol of our review.25 The following five 
databases were searched: Ovid Medline, PubMed, Embase, 
CINAHL, and the Cochrane Database of Systematic Reviews. 
In addition, we performed a hand search of reference lists of 
systematic reviews captured in the original search. We used 
medical subject headings,29 and their synonyms as search 
terms. We used syntax suitable to detect different spelling 
and truncation of search terms for the various databases. 
Search terms principally related to interventions were 
“guideline/protocol”, “adherence”, “impact”, “evaluation”, 



































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1




Impact of interventions on vancomycin dosing and monitoring
rial”, “seminar”, “feedback”, “reminder”, “electronic mail”, 
“smartphone”, “computer”, “personal digital assistant; and 
outcomes”, “prescribing”, “dosing”, “drug monitoring”, 
and “monitoring”. This list is not exhaustive: the full search 
strategy is included as the Supplementary material. The 
search was rerun in May 2018 to identify any potentially 
new citations that had been published prior to submission.
Data management and extraction
All citations captured were stored in a dedicated and shared 
library using EndNote referencing software (version X7.7; 
Clarivate Analytics, Philadelphia, PA, USA). Titles and 
abstracts of studies were reviewed and assessed independently 
by two authors for suitability of inclusion. Two authors (CJP 
and AJW) independently reviewed the full text of relevant 
studies, any disagreement was resolved by a third investiga-
tor. Studies that satisfied eligibility were included for data 
extraction. Two authors piloted the data-extraction tool before 
agreeing on the final tool, which was employed using Excel 
(Microsoft, Seattle, WA, USA). The data-extraction tool was 
located in cloud storage (Dropbox version 16.4.30; Dropbox, 
San Francisco, CA, USA) to enable shared and remote access 
by authors. Data collected included author, year, country, 
study design, type of intervention, description of interven-
tions, and outcome measures.
Outcome measures
Data were collected for outcome measures of vancomycin 
dosing. Loading dosages and maintenance dosages appro-
priate for renal function were as defined by individual study 
Records identified through database
searches
(n=12,483)
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authors. TDM outcomes were the timing of blood samples 
at steady-state concentration (ie, blood taken prior to the 
fourth or fifth dose with 12-hourly dosing in patients with 
normal renal function),9 appropriate timing of trough levels 
(ie, prior to next dose),8 attainment of therapeutic target,8,10 
and frequency of patients with supratherapeutic vancomycin 
concentration (>20 mg/L, at which likelihood nephrotoxic-
ity increases steeply).30 The safety outcome of frequency 
of reported nephrotoxicity was also included, defined as an 
increase in serum creatinine of 0.5 mg/dL or >50% from 
baseline on two or more consecutive measurements after ≥2 
days of vancomycin therapy.31
Interventions
We categorized interventions according to the Cochrane 
Effective Practice and Organization of Care Group (EPCO) 
taxonomy of health-system interventions. The four catego-
ries of this taxonomy are delivery arrangement, financial 
arrangements, governance arrangement, and implementation 
strategies. Implementation strategies are further subdivided 
into interventions targeted at health care workers. In this 
subdivision, the interventions are audit and feedback, clinical 
incident monitoring, monitoring the performance and deliv-
ery of health care, communities of practice, continuous qual-
ity improvement, educational games, educational materials, 
educational meetings, educational outreach, clinical practice 
guidelines, interprofessional education, local consensus 
processes, local opinion leaders, managerial supervision, 
patient-mediated interventions, public release of performance 
data, reminders, routine patient-reported outcome measures, 
and tailored interventions.32 The target cohort of interventions 
was hospital clinicians. For definition purposes in this review, 
patients treated by staff who were subject to interventions are 
referred to as the intervention group. Patients under the care 
of hospital clinicians that were not subject to interventions 
are referred to the usual-care group.
Risk of bias
Quality assessment of included studies was performed using 
ROBINS-I (risk of bias in nonrandomized studies – interven-
tions). ROBINS-I was developed by members of the Cochrane 
Bias Methods Group and Non-Randomized Studies Methods 
Group and has been validated.33 As all studies in this review 
were nonrandomized and conducted in a health care environ-
ment, the ROBINS-I tool was highly suitable. ROBINS-I 
contains seven domains of bias: due to confounding, selec-
tion of participants, classification of interventions, deviations 
from intended interventions, missing data, measurements of 
outcomes, and selection of reported results. ROBINS-I pro-
vides detailed guidance on categorizing each domain as low 
risk, moderate risk, serious, or critical risk of bias. ROBINS-I 
detailed guidance states that the level of risk of bias can only 
be as good as the highest risk obtained for any one of the 
seven domains, and it is unlikely that an observational study 
will be judged less than moderate risk.33 Two authors (CJP 
and AJW) independently assessed studies for quality, with any 
disagreement resolved by a third author (Figure 2).
Statistical analysis
Event rates for intervention and standard care are described 
using frequencies and proportions and differences described 
using ORs with 95% CIs in Stata (version 15.1; StataCorp, 
College Station, TX, USA) using the epitab “cci” command. 
We performed random-effect meta-analyses for the various 
study subgroups with inverse-variance weights using the R 
“meta” package (version 4.9.1) with R software (version 3.4.1; 
Vienna, Austria). Forest plots were created using RevMan ver-
sion 5.0 (Nordic Cochrane Center, Copenhagen, Denmark). 
Heterogeneity was assessed using t2 and I2. I2=0 represents no 
heterogeneity, while increasing values represent the presence 
of heterogeneity. I2 values of 25%, 50%, and 75% were defined 
as low, moderate, and high heterogeneity respectively.34
Results
Search results
The search captured 12,483 records across five databases. 
Following duplicate removal, 10,036 citations were screened 
and 93 full-text articles sourced, with 89 subsequently 
excluded (Figure 1). Four studies met inclusion criteria. 
This was increased to six after the search was rerun prior 
to submission. All studies included were observational, and 
no randomized controlled studies were identified. Studies 















Bias in selection of participants into the study
Bias in classification of interventions
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Figure 2 Quality of included studies: ROBINS-I (risk of bias assessment in nonran-
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Impact of interventions on vancomycin dosing and monitoring
involving interventions employing single or multifaceted 
interventions were included.
Quality of studies and risk of bias
Five of six included studies had at least one domain that was 
assessed as moderate risk of bias, and one study had a serious 
risk of bias for two domains. No studies had domains ranked 
as critical risk of bias. Figure 2 shows the assignment of risk 
of bias for each of the seven domains of each included study. 
Overall risk of bias for each study is presented in Table 1.
Characteristics of included studies
Five of the six studies were from the US35,36,38–40 and one from 
Australia.37 Three studies reported the population as number 
of patients, with 263 in the intervention group and 274 receiv-
ing usual care,35–37 and one study reported treatment courses, 
with 200 in the intervention group and 279 receiving usual 
care.38 Two studies that evaluated timing of blood samples for 
vancomycin assays exclusively reported only the number of 
concentrations: 387 in the intervention group and 288 receiv-
ing usual care.39,40 Data on characteristics of included studies 
and details of intervention are summarized in Tables 1 and 2.
Interventions
All interventions involved education meetings.35–40 Five stud-
ies employed multifaceted interventions,35–38,40 including two 
or more interventions. Two studies involved implementation 
of guidance, educational meetings, and dissemination of 
educational materials.37,38 Two studies employed guidance 
and education meetings,36 one utilized education meetings 
and dissemination of educational material,40 and another used 
educational meetings only.39 Of the four studies using guidance, 
two employed a clinical practice guideline,37,38 one a nomo-
gram,36 and one an undefined policy change.35 Dissemination 
of educational materials was employed in three studies using 
a pocket reference card (Table 2).37,38,40 Reported outcomes 
and effect sizes for studies employing interventions on dos-
ing, monitoring, and nephrotoxicity outcomes are presented 
in Table 3. Interventions involving implementation of clinical 
practice guidelines, educational meetings, and dissemination 
of educational resources had the highest effect on dosing 
outcomes (effect size 2.76–7.28, P<0.001).37,38 Furthermore, 
studies using these three interventions when assessing initial 
maintenance doses being prescribed appropriate for renal 
function demonstrated relatively consistent effect sizes: OR 
2.76 (95% CI 1.66–4.58, P<0.001)37 and OR 3.36 (95% CI 
2.22–5.09, P<0.001).38 Overwhelmingly, the studies employ-
ing a composite of implementation of guidelines, educational 
meetings, and dissemination of educational material also had 
the greatest effect on TDM outcomes. A notable exception was 
one study using educational meetings and dissemination of 
educational material, which produced a greater effect size (OR 
4.2, 95% CI 1.16–15.17; P=0.024)40 when compared with stud-
ies that used three interventions: OR 2.18 (95% CI 1.43–3.32, 
P<0.001)38 and OR 1.42 (95% CI 0.87–2.32, P=0.162).37
Outcome measures
Effect of interventions on dosing of vancomycin
The overall effect of interventions on vancomycin dosing 
was OR 2.50 (95% CI 1.29–4.84, P<0.01). The heterogeneity 
between studies was high (I2=83%, P<0.01; Figure 3). Three 
studies measured the impact of interventions on loading 
doses.35–37 The overall frequency of receiving a loading dose 
for patients in the intervention group (112 of 263, 42.6%) com-
pared to those receiving usual care (69 of 274, 25.2%) was not 
significantly different (OR 2.08, 95% CI 0.49–8.79; P=0.32). 
High heterogeneity among those studies was present (I2=90%, 
P<0.01; Figure 3A). There were two studies that measured the 
effect of interventions on maintenance dosages appropriate for 
renal function.37,38 There was a higher frequency of maintenance 
dosages prescribed for patients in the intervention group (246 of 
333, 73.9%) compared to those receiving usual care (183 of 378, 
48.4%; OR 3.11, 95% CI 2.26–4.28; P<0.01). There was low 
heterogeneity between these studies (I2=0, P=0.55; Figure 3B).
Effect of interventions on monitoring of vancomycin
Three studies evaluated the effect of interventions on whether 
blood samples were collected at steady-state concentra-
tion.37,38,40 There was a higher proportion of concentrations 
appropriately collected at steady state (196 of 356, 55.1%) for 
patients in the intervention group compared to those receiving 
usual care (122 of 314, 38.9%; OR 1.95, 95% CI 1.26–3.02; 
P<0.01) There was no significant heterogeneity between stud-
ies (I2=38%, P=0.20; Figure 4A). Three studies measured 
the effect of interventions on appropriate timing of trough 
blood samples for vancomycin assays prior to next dose.35,38,39 
There was no difference between patients in the intervention 
group (463 of 668, 69.3%) and those receiving usual care 
(302 of 569, 53.1%; OR 2.02, 95% CI 0.72–5.72; P=0.18), 
although there was significant heterogeneity between these 
studies (I2=94%, (P<0.01; Figure 4B).
There was no significant difference in patient attainment 
of therapeutic target between those in the intervention group 
(161 of 233, 69.1%) and those receiving usual care (144 
of 225, 64%; OR 1.50, 95% CI 0.49–4.63; P=0.48). There 
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Note: *Indicates serum vancomycin concentrations.
Abbreviations: NR, not reported; CPG, clinical practice guideline; EM, educational meeting; EPOC, Effective Practice and Organisation of Care (Cochrane).
P=0.02; Figure 4C). No association was seen between the 
frequency of patients attaining potentially toxic suprath-
erapeutic vancomycin levels above target (>20 mg/L) in the 
intervention group (102 of 233, 43.8%) and those receiving 
usual care (143 of 225, 63.6%; OR 0.45, 95% CI 0.11–1.83; 
P=0.26). There was significant heterogeneity between these 
studies (I2=92%, (P<0.01; Figure 5A).
Effect of interventions on frequency of 
nephrotoxicity
There were two studies reporting the number of patients that 
experienced nephrotoxicity. No association was observed 
between patients in the intervention group (23 of 233, 9.9%) 
and those receiving usual care (29 of 225, 12.9%; OR 0.75, 
95% CI 0.42–1.34; P=0.33). There was low heterogeneity 
between these studies (I2=0, P=0.60; Figure 5B).
Discussion
To our knowledge, this is the first systematic review with 
meta-analysis to explore the effect of commonly recom-
mended interventions of educational meetings, implementa-
tion of guidance, and dissemination of educational materials 
on vancomycin dosing, monitoring, and nephrotoxicity. We 
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Impact of interventions on vancomycin dosing and monitoring
a variable effect on dosing, monitoring, and nephrotoxicity 
outcomes. All studies employed a constant of educational 
meetings. A Cochrane review on the effect of educational 
meetings on professional-practice health care outcomes 
found that educational meetings had a modest effect (median 
6%, IQR 1.8%–15.9%) on these outcomes when compared 
to no intervention.22 This is broadly consistent with our find-
ings when educational meetings were the sole intervention. 
While no included study used dissemination of educational 
material exclusively as an intervention, one study that used 
this in conjunction with educational meetings demonstrated a 
much higher effect change of 34%, although this was a small 
study.40 A Cochrane review of the effect of disseminating 
educational materials to medical officers found a minimally 
Study or
Subgroup
Treatment Standard Odds ratio
Events

























Test for overall effect: Z=0.99 (P=0.32)
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Test for overall effect: Z=6.93 (P<0.01)
Heterogeneity: 2=0; 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Total Total
Figure 3 Effect of interventions on vancomycin dosing.
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increased effect (median 2%, range 0–11%) when compared 
to no intervention, but an increased effect (median 13%, range 
16%–36%) was observed when interventions were followed 
up to 9 months.41
The US Institute of Medicine recommends promoting 
multifaceted interventions to implement guidelines at indi-
vidual practitioner and health care system levels.20 However, 
some authors have expressed strongly that multifaceted inter-
ventions are no better when compared to single interventions 
in changing health care professionals’ behaviour.42 This was 
inconsistent with our findings. Five of the six included stud-
ies used multifaceted interventions to improve dosing and 
monitoring of vancomycin. While the effect of individual 
interventions when combined do not appear to have had a pro-
portional summative effect, those studies with interventions 
that specifically employed a guideline, educational meetings, 
and dissemination of educational materials generally had a 
much greater composite effect than individual interventional 
component effects.
Others have stated that providing printed material is a 
reasonable intervention to consider in any implementation 
strategy, as the costs are not likely to be prohibitive.43 Based 
on the findings of this review, we agree with this recommen-
dation for educational material to aid dosing and monitoring 
of vancomycin. Two studies37,38 with similar interventions 
that produced favorable effect size changes also adapted 
their local vancomycin guidelines from US consensus 
guidelines. This may be meaningful, as guideline content 
and usability have also been acknowledged as variables in 
implementation strategies.20 One of the included studies37 
had a very detailed description of its educational component 
published elsewhere44 and stated use of additional interven-
tions, including audit and feedback, local consensus pro-
cesses, opinion leaders in development of guidelines, and 
email reminder.45,46 It is possible these interventions may 
have augmented some of the generally large effect changes 
observed within that study.
Interestingly no included studies provided assessment 
of the local barriers and enablers to effective dosing and 
monitoring of vancomycin in their institution. Understand-
ing these barriers and enablers can influence the choice 
of intervention, as has been reported by health care pro-
fessionals conducting implementation projects in health 
care, including a project to improve vancomycin dosing 
and monitoring.47 Additionally, no included studies pro-
vided any theoretical or behavioral basis for selecting the 
interventions they employed. Providing a theoretical basis 
for selecting interventions is increasingly acknowledged 
as important for any implementation program seeking to 
influence health-professional behaviour.48–51 Furthermore, 
the results of this systematic review and meta-analysis are 
likely to be applicable to the selection of interventions that 
optimize the uptake of other health care initiatives in hospi-
tals, particularly those relating to more complex prescribing 
processes. Another strategy used to implement changes in 
clinical practice for antibiotic dosing has been the use of 
clinical decision-support software.52 However, a Cochrane 
review found that while this was useful for the dosing and 
monitoring of some antibiotics, there was no evidence for 
vancomycin.53 Implementing a vancomycin nomogram 
utilizing computerized prescriber-order entry systems has 
shown to be useful and results in an increased likelihood 
Study or
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of prescribers ordering initial regimens that are nomogram 
adherent.54 For institutions operating electronic prescribing, 
computerized prescriber-order entry is likely to be seen more 
in the future. Furthermore, smartphone applications provide 
ready access to contemporary guidance on the use of antibi-
otics, including vancomycin.55 However, data are lacking on 
whether access to smartphone applications improves dosing 
and monitoring of vancomycin.
Our study has some limitations. Our search was restricted 
to English-language citations, so it is possible we did not 
capture all relevant studies. While we designed a systematic 
search with the assistance of an experienced medical liai-
son librarian, the final number of included studies was low, 
and thus our conclusions are derived from a small number 
of studies. There was considerable heterogeneity among 
included studies, in particular for sample size, duration of 
intervention, details of hospital environment, attitudes, and 
qualifications and experience of health care professionals. 
The sustainability of effects once the interventions have 
concluded is an important question that we were unable to 
answer in this review. Details about the interventions were at 
times minimal, limiting utility of comparisons between inter-
ventions. Additionally, with the data from this review, we are 
unable to determine the impact of the various interventions 
on clinical outcomes, aside from nephrotoxicity. Lastly, 
in an effort to account for heterogeneity among studies, a 
random-effect model with weighting using inverse-variance 
methods was used.56
Conclusion
Prolonging the working life of vancomycin is critical in our 
armamentarium of antibiotics in this era of antimicrobial 
resistance. Interventions that have favorable effects on dos-
ing and monitoring of vancomycin should be adopted at an 
individual professional level and more broadly, across health 
systems, as inappropriate dosing can lead to therapeutic 
failure, nephrotoxicity, and the emergence of organisms 
resistant to vancomycin. When designing implementation 
strategies targeting the dosing and monitoring of vancomycin, 
multifaceted interventions are more effective. Consideration 
should also be given to the local barriers and enablers that 
will have an impact on practice initiatives seeking to improve 
the use of vancomycin. This review found that multifaceted 
interventions including guideline implementation, face-to-
face educational meetings, and dissemination of educational 
resources in the form of pocket dosing and TDM cards had a 
favorable effect on the dosing and monitoring of vancomycin 
in hospitalized patients.
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Search strategy for Ovid Medline
1. Vancomycin/
2. (vancocin or vancomycin).tw,kw.
3. 1 or 2
4. education, continuing/or education, medical, continuing/
or education, nursing, continuing/or education, pharmacy, 
continuing/or education, professional, retraining/
5. Practice Guideline/or Guideline/or Guideline Adherence/
6. guideline*.tw,kw.
7. (guideline* adj3 (adherenc* or evaluat* or introduct* 
or impact* or effect* or disseminat* or implement* or 
integrat*)).tw,kw.
8. Electronic Mail/
9. ((writte* or print* or oral or online* or educat*) adj2 
(information or material*)).tw,kw.
10. (face to face or face-to-face or train* or lectur* or 
tutor* or seminar* or workshop* or academic detail*).
tw,kw.
11. (opinion leader* or facilitator* or “linking agent*” or 
champion or “changing agent*”).mp.
12. ((knowlege or research) adj2 (translant* or transfer* or 








20. (protocol* or algorithm* or leaflet* or pamphlet*).tw,kw.
21. computers, handheld/or minicomputers/
22. (mobile* or “cell phone*” or “smart phone*” or smart-
phone*).tw,kw.
23. ((app$1 or application*) adj3 (phone* or mobile* or 
cell*)).tw,kw.
24. Drug Monitoring/
25. (prescri* or monitor* or dosag* or dosing).ti.
26. or/4-25
27. 3 and 26
28. limit 27 to english language
29. (note or letter or editorial or comment).pt.
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